Characterization of 2-(2,6-dichloro-benzyl)-thiazolo[5,4-d]pyrimidin-7-yl]- (4-trifluoromethyl-phenyl)-amine (JNJ-39729209) as a novel TRPV1 antagonist

European Journal of Pharmacology

Volumn 663, Issue 1-3, 2011, Pages 40-50

  Maher, Michael P ^a   Bhattacharya, Anindya ^a   Ao, Hong ^a   Swanson, Nadia ^a   Wu, Nyan Tsz ^a   Freedman, Jamie ^a   Kansagara, Mena ^a   Scott, Brian ^a   Li, Dong H ^a   Eckert III, William A ^a   Liu, Yi ^a   Sepassi, Kia ^a   Rizzolio, Michele ^a   Fitzgerald, Anne ^a   Liu, Jing ^a   Branstetter, Bryan J ^a   Rech, Jason C ^a   Lebsack, Alec D ^a   Breitenbucher, J Guy ^a   Wickenden, Alan D ^a   Chaplan, Sandra R ^a   more..

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Capsaicin; Cough; Ion channels; Pain; TRPV1; Vanilloid receptor

Indexed keywords

2 [(2,6 DICHLOROBENZYL)THIAZOLO[5,4 D]PYRIMIDIN 7 YL](4 TRIFLUOROMETHYLPHENYL)AMINE; CAPSAICIN; CARRAGEENAN; JNJ 39729209; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTHERMIA; HYPOTENSION; HYPOTHERMIA; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BODY TEMPERATURE; CELL LINE; CLINICAL TRIALS AS TOPIC; COUGH; DOGS; FEMALE; GUINEA PIGS; HUMANS; HYPERALGESIA; HYPOTENSION; MALE; MICE; PYRIMIDINES; RATS; THIAZOLES; TRPV CATION CHANNELS;

EID: 79959289728     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.05.001     Document Type: Article

References (37)

1. Ahern, G.P., Wang, X., Miyares, R.L., 2006. Polyamines are potent ligands for the capsaicin receptor TRPV1. J. Biol. Chem. 281, 8991-8995.
2. Bhattacharya, A., Scott, B.P., Nasser, N., Ao, H., Maher, M.P., Dubin, A.E., Swanson, D.M., Shankley, N.P., Wickenden, A.D., Chaplan, S.R., 2007. Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)- piperazine-1-carboxylic acid (5- trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. J. Pharmacol. Exp. Ther. 323, 665-674.
3. Branstetter, B., Breitenbucher, J.G., Lebsack, A.D., Liu, J., Rech, J.C., Xiao, W., 2009. Preparation of imidazolo-, oxazolo-, and thiazolopyrimidine compounds as modulators of transient receptor potential protein vanilloid receptor 1 (TRPV1) activity. . US 2009156599.
4. Caterina, M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., Julius, D., 1997. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816-824. (Pubitemid 27462969)
5. Caterina, M.J., Leffler, A., Malmberg, A.B., Martin, W.J., Trafton, J., Petersen-Zeitz, K.R., Koltzenburg, M., Basbaum, A.I., Julius, D., 2000. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288, 306-313. (Pubitemid 30226186)
6. Chizh, B.A., O'Donnell, M.B., Napolitano, A., Wang, J., Brooke, A.C., Aylott, M.C., Bullman, J.N., Gray, E.J., Lai, R.Y., Williams, P.M., Appleby, J.M., 2007. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 132, 132-141. (Pubitemid 47494566)
7. Crutchlow, M., 2009. Pharmacological inhibition of TRPV1 impairs sensation of potentially injurious heat in healthy subjects. ASCPT 110th Annual Meeting March 18-21.
8. Cui, M., Honore, P., Zhong, C., Gauvin, D., Mikusa, J., Hernandez, G., Chandran, P., Gomtsyan, A., Brown, B., Bayburt, E.K., Marsh, K., Bianchi, B., McDonald, H., Niforatos, W., Neelands, T.R., Moreland, R.B., Decker, M.W., Lee, C.H., Sullivan, J.P., Faltynek, C.R., 2006. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci. 26, 9385-9393. (Pubitemid 44396851)
9. Davis, J.B., Gray, J., Gunthorpe, M.J., Hatcher, J.P., Davey, P.T., Overend, P., Harries, M.H., Latcham, J., Clapham, C., Atkinson, K., Hughes, S.A., Rance, K., Grau, E., Harper, A.J., Pugh, P.L., Rogers, D.C., Bingham, S., Randall, A., Sheardown, S.A., 2000. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405, 183-187. (Pubitemid 30313536)
10. Gavva, N.R., Bannon, A.W., Hovland Jr., D.N., Lehto, S.G., Klionsky, L., Surapaneni, S., Immke, D.C., Henley, C., Arik, L., Bak, A., Davis, J., Ernst, N., Hever, G., Kuang, R., Shi, L., Tamir, R., Wang, J., Wang, W., Zajic, G., Zhu, D., Norman, M.H., Louis, J.C., Magal, E., Treanor, J.J., 2007a. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther. 323, 128-137.
11. Gavva, N.R., Bannon, A.W., Surapaneni, S., Hovland Jr., D.N., Lehto, S.G., Gore, A., Juan, T., Deng, H., Han, B., Klionsky, L., Kuang, R., Le, A., Tamir, R., Wang, J., Youngblood, B., Zhu, D., Norman, M.H., Magal, E., Treanor, J.J., Louis, J.C., 2007b. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci. 27, 3366-3374. (Pubitemid 46515121)
12. Gavva, N.R., Treanor, J.J., Garami, A., Fang, L., Surapaneni, S., Akrami, A., Alvarez, F., Bak, A., Darling, M., Gore, A., Jang, G.R., Kesslak, J.P., Ni, L., Norman, M.H., Palluconi, G., Rose, M.J., Salfi, M., Tan, E., Romanovsky, A.A., Banfield, C., Davar, G., 2008. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136, 202-210.
13. Honore, P., Chandran, P., Hernandez, G., Gauvin, D.M., Mikusa, J.P., Zhong, C., Joshi, S.K., Ghilardi, J.R., Sevcik, M.A., Fryer, R.M., Segreti, J.A., Banfor, P.N., Marsh, K., Neelands, T., Bayburt, E., Daanen, J.F., Gomtsyan, A., Lee, C.H., Kort, M.E., Reilly, R.M., Surowy, C.S., Kym, P.R., Mantyh, P.W., Sullivan, J.P., Jarvis, M.F., Faltynek, C.R., 2009. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain 142, 27-35.
14. Jia, Y., McLeod, R.L., Hey, J.A., 2005. TRPV1 receptor: a target for the treatment of pain, cough, airway disease and urinary incontinence. Drug News Perspect. 18, 165-171. (Pubitemid 40704837)
15. Kym, P.R., Kort, M.E., Hutchins, C.W., 2009. Analgesic potential of TRPV1 antagonists. Biochem. Pharmacol. 78, 211-216.
16. Lambert, G.A., Davis, J.B., Appleby, J.M., Chizh, B.A., Hoskin, K.L., Zagami, A.S., 2009. The effects of the TRPV1 receptor antagonist SB-705498 on trigeminovascular sensitisation and neurotransmission. Naunyn Schmiedebergs Arch. Pharmacol. 380, 311-325.
17. Lehto, S., Tamir, R., Deng, H., Klionsky, L., Kuang, R., Le, A., Lee, D., Louis, J.C., Magal, E., Manning, B.H., Rubino, J., Surapaneni, S., Tamayo, N., Wang, T., Wang, J., Wang, J., Wang, W., Youngblood, B., Zhang, M., Zhu, D., Norman, M., Gavva, N.R., 2008. Antihyperalgesic effects of AMG8562, a novel vanilloid receptor TRPV1 modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Ther. 326 (1), 218-229.
18. Lilley, E., Panesar, M., Head, V., Nash, M., Fox, A., 2008. Two TRPV1 antagonists with distinct profiles on mechanical hyperalgesia and core temperature in rats. pA2 Online BPS Winter Meeting 2008 (abstract), 075P.
19. Liu, Y., Lubin, M.L., Reitz, T.L., Wang, Y., Colburn, R.W., Flores, C.M., Qin, N., 2006. Molecular identification and functional characterization of a temperature-sensitive transient receptor potential channel (TRPM8) from canine. Eur. J. Pharmacol. 530, 23-32.
20. Maher, M., Ao, H., Banke, T., Nasser, N., Wu, N.T., Breitenbucher, J.G., Chaplan, S.R., Wickenden, A.D., 2008. Activation of TRPA1 by farnesyl thiosalicylic acid. Mol. Pharmacol. 73, 1225-1234.
21. Mills, C., McMackin, M., Jaffe, R., Yu, J., Zininberg, E., Slee, D., Gogas, K., Bradbury, M., 2008. Effects of the transient receptor potential vanilloid 1 antagonist A-425619 on body temperature and thermoregulation in the rat. Neuroscience 156, 165-174.
22. Neeper, M.P., Liu, Y., Hutchinson, T.L., Wang, Y., Flores, C.M., Qin, N., 2007. Activation properties of heterologously expressed mammalian TRPV2: evidence for species dependence. J. Biol. Chem. 282, 15894-15902.
23. Pomonis, J.D., Harrison, J.E., Mark, L., Bristol, D.R., Valenzano, K.J., Walker, K., 2003. N-(4- Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine -1(2H)-car-box-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 306, 387-393.
24. Rami, H.K., Thompson, M., Stemp, G., Fell, S., Jerman, J.C., Stevens, A.J., Smart, D., Sargent, B., Sanderson, D., Randall, A.D., Gunthorpe, M.J., Davis, J.B., 2006. Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg. Med. Chem. Lett. 16, 3287-3291.
25. Ross, R.A., 2003. Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol. 140, 790-801.
26. Smart, D., Gunthorpe, M.J., Jerman, J.C., Nasir, S., Gray, J., Muir, A.I., Chambers, J.K., Randall, A.D., Davis, J.B., 2000. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129, 227-230. (Pubitemid 30072640)
27. Rowbotham, M.C., Nothaft, W., Duan, W.R., Wang, Y., Faltynek, C., McGaraughty, S., Chu, K.L., Svensson, P., 2011. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain 152, 1192-1200.
28. Steiner, A.A., Turek, V.F., Almeida, M.C., Burmeister, J.J., Oliveira, D.L., Roberts, J.L., Bannon, A.W., Norman, M.H., Louis, J.C., Treanor, J.J., Gavva, N.R., Romanovsky, A.A., 2007. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J. Neurosci. 27, 7459-7468. (Pubitemid 47066573)
29. Swanson, D.M., Dubin, A.E., Shah, C., Nasser, N., Chang, L., Dax, S.L., Jetter, M., Breitenbucher, J.G., Liu, C., Mazur, C., Lord, B., Gonzales, L., Hoey, K., Rizzolio, M., Bogenstaetter, M., Codd, E.E., Lee, D.H., Zhang, S.P., Chaplan, S.R., Carruthers, N.I., 2005. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48, 1857-1872.
30. Szallasi, A., Cruz, F., Geppetti, P., 2006. TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol. Med. 12, 545-554. (Pubitemid 44633805)
31. Szallasi, A., Cortright, D.N., Blum, C.A., Eid, S.R., 2007. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discov. 6, 357-372.
32. Tamayo, N., Liao, H., Stec, M.M., Wang, X., Chakrabarti, P., Retz, D., Doherty, E.M., Surapaneni, S., Tamir, R., Bannon, A.W., Gavva, N.R., Norman, M.H., 2008. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. J. Med. Chem. 51, 2744-2757.
33. Tominaga, M., Tominaga, T., 2005. Structure and function of TRPV1. Pflugers Arch. 451, 143-150. (Pubitemid 41424917)
34. Tominaga, M., Caterina, M.J., Malmberg, A.B., Rosen, T.A., Gilbert, H., Skinner, K., Raumann, B.E., Basbaum, A.I., Julius, D., 1998. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21, 531-543. (Pubitemid 28475505)
35. Walker, K.M., Urban, L., Medhurst, S.J., Patel, S., Panesar, M., Fox, A.J., McIntyre, P., 2003. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 304, 56-62.
36. Wong, G.Y., Gavva, N.R., 2009. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: recent advances and setbacks. Brain Res. Rev. 60, 267-277.
37. Zygmunt, P.M., Petersson, J., Andersson, D.A., Chuang, H.-H., Sorgard, M., Di Marzo, V., Julius, D., Hogestatt, E.D., 1999. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature (London) 400, 452-457. (Pubitemid 29361798)